<DOC>
	<DOC>NCT01750957</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523 or placebo orally daily for 12 weeks.</brief_summary>
	<brief_title>A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Children and adolescents, 5 to 13 years of age Diagnosis of fragile X syndrome based on prior DNA testing confirming Fragile X Mental Retardation 1 (FMR1) full mutation and qualifying scores on the ABC and CGIS Previous treatment with another mGlu5 receptor antagonist within the prior 3 months Participation in a clinical trial involving an investigational drug (unapproved) or nondrug treatment within the prior 6 weeks or 5 times the halflife (whichever is longer) before the start of this study Any uncontrolled, unstable clinically significant psychiatric condition other than fragile X syndrome History of suicidal behavior Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>